Drug Delivery
Halozyme and Baxter make Hylenex available in U.S. for subcutaneous delivery of medications, fluids
Published in Drug Week, July 28th, 2006
"Hylenex is the first and only FDA (U.S. Food & Drug Administration) - approved recombinant human hyaluronidase drug product, and we are proud to make it available to healthcare providers as a way to simplify the delivery of medications and fluids and, ultimately, provide a more comfortable patient experience," said Jonathan Lim, MD, president and CEO of Halozyme.
The companies will focus predominantly on making the product available to hospices and palliative...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2006-07-28)
More Articles from Drug Week
- Colorectal Cancer
Adventrx initiates CoFactor phase III clinical trial for metastatic colorectal cancer - Diabetes Therapy
Exenatide improved HbA1c , weight and some cardiovascular risk factors in type 2 diabetes - Drug Development
Chimerix announces initiation of Phase I clinical trials of CMX001, an oral smallpox treatment - Insulin Resistance
Insmed presents positive Iplex data for Leprechaunism and Type A syndrome - AIDS-Related Lymphoma
HIV score, IPI score and HAART affects survival in AIDS-related non-Hodgkin lymphoma - Acute Myocardial Infarction
Alexion reports APEX-AMI study does not achieve mortality reduction in heart attack patients - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
